The effect of chronic oral defibrotide on platelet function, vascular PG1 2 generation,
atherosclerotic plaque formation and serum lipids was studied in rabbits. The animals were …

Defibrotide,(D) an antithrombotic agent, when administered iv to cholesterol-fed rabbits
decreased cholesterol in the aorta without changing total plasma cholesterol, triglyceride or …

The aim of the present work was to assess if the cardioprotective drug defibrotide could
counteract the hypercholesterolemia noxious effects on cardiovascular function. Aortas and …

In a previous paper we gave evidence that chronic oral defibrotide antagonizes the noxious
effect of developing atherosclerosis in the cardiovascular system. In the present paper we …

Defibrotide, a polydeoxyribonucleotide, has been found to modulate endothelial cell
function, causing an increase in tissue plasminogen activator (t-PA) levels, a decrease in …

Defibrotide is a polydeoxyribonucleotide extracted from mammalian organs (porcine) and
prepared by controlled depolymerization, resulting in a single-stranded deoxyribonucleotide …

Defibrotide is a polynucleotide extracted from mammalian lung, which shows antithrombotic
and anti-ischaemic activity in animals, probably related to stimulation of fibrinolysis and/or …

Defibrotide is a partially depolymerized DNA fraction, having a molecular weight of about
20,000 and possessing antithrombotic and fibrinolytic activities. The present study was …

MATERIALS AND METHODS This study started in November 1986 and fin ished in July
1987. The investigation was carried out on 10 patients (8 men, 2 women, ages 41 to 77 …

The antithrombotic drug Defibrotide (DFT)(a polydeoxyribonucleotide with a mean MW of
20,000 Daltons) reduces the number of leukocytes and platelets in thrombi. Because …